Key result
Molecular PET imaging detects early disease activity in aortic stenosis before severe calcification develops.
Why the study?
Medical therapies capable of slowing aortic valve stenosis progression remain unavailable, highlighting the need for molecular imaging technologies to non-invasively assess disease progression and evaluate medical interventions.
Can molecular imaging with positron emission tomography assess early disease progression and pathophysiology in patients with aortic valve stenosis?
Can molecular imaging with positron emission tomography assess early disease progression and pathophysiology in patients with aortic valve stenosis?
Answers are grounded in this paper and cite their sources.
Molecular PET imaging shows potential for identifying pre-calcific, active stages of aortic valve stenosis, which may eventually help in evaluating novel medical therapies.
Aortic valve stenosis (AVS) is an increasingly prevalent disease in our aging population. Although multiple risk factors for AVS have been elucidated, medical therapies capable of slowing down disease progression remain unavailable. Molecular imaging technologies are opening up avenues for the non-invasive assessment of disease progression, allowing the assessment of (early) medical interventions. This review will focus on the role of positron emission tomography of the aortic valve with 18F-fluorodeoxyglucose and 18F-sodium fluoride but will also shed light on novel tracers which have potential in AVS, ranging from the healthy aortic valve to end-stage valvular disease.
No takes yet. Share an insight, caveat, or question.
Oostveen et al. (2022) conducted a review in Aortic valve stenosis (AVS). Positron emission tomography (PET) molecular imaging was evaluated. Positron emission tomography using 18F-NaF and 18F-FDG offers a promising non-invasive approach to detect early disease progression in aortic valve stenosis prior to severe calcification.
Synapse has enriched 10 related papers. Consider them for comparative context: